120 related articles for article (PubMed ID: 25924988)
1. Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond.
Koch C; Trojan J
Digestion; 2015; 91(4):294-302. PubMed ID: 25924988
[TBL] [Abstract][Full Text] [Related]
2. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
3. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors to targeted treatment in gastrointestinal carcinomas.
Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
[TBL] [Abstract][Full Text] [Related]
6. New trends in molecular and cellular biomarker discovery for colorectal cancer.
Aghagolzadeh P; Radpour R
World J Gastroenterol; 2016 Jul; 22(25):5678-93. PubMed ID: 27433083
[TBL] [Abstract][Full Text] [Related]
7. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
[TBL] [Abstract][Full Text] [Related]
8. Strategies to design clinical studies to identify predictive biomarkers in cancer research.
Perez-Gracia JL; Sanmamed MF; Bosch A; Patiño-Garcia A; Schalper KA; Segura V; Bellmunt J; Tabernero J; Sweeney CJ; Choueiri TK; Martín M; Fusco JP; Rodriguez-Ruiz ME; Calvo A; Prior C; Paz-Ares L; Pio R; Gonzalez-Billalabeitia E; Gonzalez Hernandez A; Páez D; Piulats JM; Gurpide A; Andueza M; de Velasco G; Pazo R; Grande E; Nicolas P; Abad-Santos F; Garcia-Donas J; Castellano D; Pajares MJ; Suarez C; Colomer R; Montuenga LM; Melero I
Cancer Treat Rev; 2017 Feb; 53():79-97. PubMed ID: 28088073
[TBL] [Abstract][Full Text] [Related]
9. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
[TBL] [Abstract][Full Text] [Related]
10. Updates in Tumor Profiling in Gastrointestinal Cancers.
Perez K; Safran HP
R I Med J (2013); 2015 Oct; 98(10):21-4. PubMed ID: 26422541
[TBL] [Abstract][Full Text] [Related]
11. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer.
Guarini C; Grassi T; Pezzicoli G; Porta C
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202896
[TBL] [Abstract][Full Text] [Related]
12. Application of immunohistochemistry in gastrointestinal and liver neoplasms: new markers and evolving practice.
Chen ZE; Lin F
Arch Pathol Lab Med; 2015 Jan; 139(1):14-23. PubMed ID: 25549141
[TBL] [Abstract][Full Text] [Related]
13. [Clinical development of biomarkers for personalized medicine].
Saito M; Yoshino T
Nihon Rinsho; 2010 Jun; 68(6):1111-6. PubMed ID: 20535964
[TBL] [Abstract][Full Text] [Related]
14. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer.
Sorenson GD
Clin Cancer Res; 2000 Jun; 6(6):2129-37. PubMed ID: 10873061
[TBL] [Abstract][Full Text] [Related]
15. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
[TBL] [Abstract][Full Text] [Related]
16. Molecular classification of colorectal cancer: a dream that can become a reality.
Gurzu S; Szentirmay Z; Jung I
Rom J Morphol Embryol; 2013; 54(2):241-5. PubMed ID: 23771065
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600E mutation-specific antibody: A review.
Ritterhouse LL; Barletta JA
Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
[TBL] [Abstract][Full Text] [Related]
18. Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues.
Tiniakos D; Spandidos DA; Kakkanas A; Pintzas A; Pollice L; Tiniakos G
Anticancer Res; 1989; 9(3):715-21. PubMed ID: 2548435
[TBL] [Abstract][Full Text] [Related]
19. HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.
Fusco N; Bosari S
World J Gastroenterol; 2016 Sep; 22(35):7926-37. PubMed ID: 27672288
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for personalized medicine in GI cancers.
Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
Mol Aspects Med; 2015 Nov; 45():14-27. PubMed ID: 26054566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
